How we treat HER2-positive brain metastases

被引：29

作者：

Stavrou, E. ^{[1
]}

Winer, E. P. ^{[1
]}

Lin, N. U. ^{[1
]}

机构：

[1] Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave, Boston, MA 02115 USA

来源：

ESMO OPEN | 2021年 / 6卷 / 05期

关键词：

HER2; HER2-positive; breast cancer; brain metastases; CNS metastases; treatment; 2-POSITIVE BREAST-CANCER; PHASE-III; TRASTUZUMAB; CAPECITABINE; LAPATINIB; TRIAL; TUCATINIB;

D O I：

10.1016/j.esmoop.2021.100256

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Overexpression of the human epidermal growth factor 2 (HER2)/neu glycoprotein receptor in breast cancer is associated with increased risk of brain metastases, especially in patients with advanced disease. Improvements in the treatment of HER2-positive breast cancer has led to prolonged survival of patients with advanced disease, but the prevention and management of central nervous system metastases still poses unique clinical challenges given the associated morbidity and mortality of this site of disease. HER2-positive brain metastases are treated with surgery, radiation (stereotactic radiosurgery or whole brain radiotherapy), and systemic therapies, and are best managed by an experienced multidisciplinary team. The present article aims to provide an overview to our approach to treatment of HER2-positive brain metastases, including a review of agents with central nervous system activity, as well as management suggestions for several nuanced clinical scenarios.

引用

页数：5

共 23 条

[1] Brain metastases after breast-conserving therapy and systemic therapy: incidence and characteristics by biologic subtype
Arvold, Nils D.
Oh, Kevin S.
Niemierko, Andrzej
Taghian, Alphonse G.
Lin, Nancy U.
Abi-Raad, Rita F.
Sreedhara, Meera
Harris, Jay R.
Alexander, Brian M.
[J]. BREAST CANCER RESEARCH AND TREATMENT, 2012, 136 (01) : 153 - 160
[2] Bevacizumab as a treatment for radiation necrosis of brain metastases post stereotactic radiosurgery
Boothe, Dustin
Young, Robert
Yamada, Yoshiya
Prager, Alisa
Chan, Timothy
Beal, Kathryn
[J]. NEURO-ONCOLOGY, 2013, 15 (09) : 1257 - 1263
[3] Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets
Brastianos, Priscilla K.
Carter, Scott L.
Santagata, Sandro
Cahill, Daniel P.
Taylor-Weiner, Amaro
Jones, Robert T.
Van Allen, Eliezer M.
Lawrence, Michael S.
Horowitz, Peleg M.
Cibulskis, Kristian
Ligon, Keith L.
Tabernero, Josep
Seoane, Joan
Martinez-Saez, Elena
Curry, William T.
Dunn, Ian F.
Paek, Sun Ha
Park, Sung-Hye
McKenna, Aaron
Chevalier, Aaron
Rosenberg, Mara
Barker, Frederick G., II
Gill, Corey M.
Van Hummelen, Paul
Thorner, Aaron R.
Johnson, Bruce E.
Hoang, Mai P.
Choueiri, Toni K.
Signoretti, Sabina
Sougnez, Carrie
Rabin, Michael S.
Lin, Nancy U.
Winer, Eric P.
Stemmer-Rachamimov, Anat
Meyerson, Matthew
Garraway, Levi
Gabriel, Stacey
Lander, Eric S.
Beroukhim, Rameen
Batchelor, Tracy T.
Baselga, Jose
Louis, David N.
Getz, Gad
Hahn, William C.
[J]. CANCER DISCOVERY, 2015, 5 (11) : 1164 - 1177
[4] TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases
Freedman, Rachel A.
Gelman, Rebecca S.
Anders, Carey K.
Melisko, Michelle E.
Parsons, Heather A.
Cropp, Anne M.
Silvestri, Kelly
Cotter, Christine M.
Componeschi, Kathryn P.
Marte, Juan M.
Connolly, Roisin M.
Moy, Beverly
Van Poznak, Catherine H.
Blackwell, Kimberly L.
Puhalla, Shannon L.
Jankowitz, Rachel C.
Smith, Karen L.
Ibrahim, Nuhad
Moynihan, Timothy J.
O'Sullivan, Ciara C.
Nangia, Julie
Niravath, Polly
Tung, Nadine
Pohlmann, Paula R.
Burns, Robyn
Rimawi, Mothaffar F.
Krop, Ian E.
Wolff, Antonio C.
Winer, Eric P.
Lin, Nancy U.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (13) : 1081 - +
[5] Holmes FA, AACR, V2021
[6] Trastuzumab deruxtecan (T-DXd) in patients with HER2+metastatic breast cancer with brain metastases: A subgroup analysis of the DESTINY-Breast01 trial.
Jerusalem, Guy Heinrich Maria
Park, Yeon Hee
Yamashita, Toshinari
Hurvitz, Sara A.
Modi, Shanu
Andre, Fabrice
Krop, Ian E.
Gonzalez, Xavier
Hall, Peter S.
You, Benoit
Saura, Cristina
Kim, Sung-Bae
Osborne, Cynthia R. C.
Sagara, Yasuaki
Tokunaga, Eriko
Liu, Yali
Cathcart, Jillian
Lee, Caleb C.
Perrin, Christophe
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[7] Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study
Lin, Nancy U.
Pegram, Mark
Sahebjam, Solmaz
Ibrahim, Nuhad
Fung, Anita
Cheng, Anna
Nicholas, Alan
Kirschbrown, Whitney
Kumthekar, Priya
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (24) : 2667 - +
[8] Lin NU, 2020, J CLIN ONCOL, V38
[9] Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial
Lin, Nancy U.
Borges, Virginia
Anders, Carey
Murthy, Rashmi K.
Paplomata, Elisavet
Hamilton, Erika
Hurvitz, Sara
Loi, Sherene
Okines, Alicia
Abramson, Vandana
Bedard, Philippe L.
Oliveira, Mafalda
Mueller, Volkmar
Zelnak, Amelia
DiGiovanna, Michael P.
Bachelot, Thomas
Chien, A. Jo
O'Regan, Ruth
Wardley, Andrew
Conlin, Alison
Cameron, David
Carey, Lisa
Curigliano, Giuseppe
Gelmon, Karen
Loibl, Sibylle
Mayor, JoAl
McGoldrick, Suzanne
An, Xuebei
Winer, Eric P.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (23) : 2610 - +
[10] Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer
Lin, Nancy U.
Dieras, Veronique
Paul, Devchand
Lossignol, Dominique
Christodoulou, Christos
Stemmler, Hans-Joachim
Roche, Henri
Liu, Minetta C.
Greil, Richard
Ciruelos, Eva
Loibl, Sibylle
Gori, Stefania
Wardley, Andrew
Yardley, Denise
Brufsky, Adam
Blum, Joanne L.
Rubin, Stephen D.
Dharan, Bernie
Steplewski, Klaudia
Zembryki, Denise
Oliva, Cristina
Roychowdhury, Debasish
Paoletti, Paolo
Winer, Eric P.
[J]. CLINICAL CANCER RESEARCH, 2009, 15 (04) : 1452 - 1459

← 1 2 3 →